全球開放式、一體化生物制藥能力和技術賦能平臺,專注于為全球生物制藥公司提供端到端研發服務的上市公司
藥(yao)(yao)(yao)明(ming)生(sheng)物(wu)(wu)(wu)(股票代碼:2269.HK)作為(wei)一家香港上(shang)市公(gong)(gong)(gong)(gong)司(si)(si),是全(quan)球(qiu)開(kai)放式(shi)、一體化(hua)(hua)生(sheng)物(wu)(wu)(wu)制(zhi)藥(yao)(yao)(yao)能力(li)和技(ji)術賦(fu)能平臺。公(gong)(gong)(gong)(gong)司(si)(si)為(wei)全(quan)球(qiu)生(sheng)物(wu)(wu)(wu)制(zhi)藥(yao)(yao)(yao)公(gong)(gong)(gong)(gong)司(si)(si)和生(sheng)物(wu)(wu)(wu)技(ji)術公(gong)(gong)(gong)(gong)司(si)(si)提供(gong)端(duan)到端(duan)研(yan)(yan)發(fa)服務,幫助任何人、任何公(gong)(gong)(gong)(gong)司(si)(si)發(fa)現(xian)(xian)、開(kai)發(fa)及生(sheng)產生(sheng)物(wu)(wu)(wu)藥(yao)(yao)(yao),實現(xian)(xian)從概念到商(shang)業化(hua)(hua)生(sheng)產的全(quan)過(guo)程(cheng),加速全(quan)球(qiu)生(sheng)物(wu)(wu)(wu)藥(yao)(yao)(yao)研(yan)(yan)發(fa)進程(cheng),降低研(yan)(yan)發(fa)成本,造福病患(huan)。截(jie)至2018年12月31日(ri),在(zai)藥(yao)(yao)(yao)明(ming)生(sheng)物(wu)(wu)(wu)平臺上(shang)研(yan)(yan)發(fa)的綜合(he)項目達205個(ge),包括97個(ge)處于(yu)臨(lin)床(chuang)前研(yan)(yan)究階(jie)段(duan),94個(ge)在(zai)臨(lin)床(chuang)早期(qi)(qi)(I期(qi)(qi),II期(qi)(qi))階(jie)段(duan),13個(ge)在(zai)后期(qi)(qi)臨(lin)床(chuang)(III期(qi)(qi))以及1個(ge)在(zai)商(shang)業化(hua)(hua)生(sheng)產階(jie)段(duan)。預計到2022年,公(gong)(gong)(gong)(gong)司(si)(si)在(zai)中國(guo)、愛(ai)爾(er)蘭、新加坡(po)、美國(guo)規劃的生(sheng)物(wu)(wu)(wu)制(zhi)藥(yao)(yao)(yao)生(sheng)產基地合(he)計產能約22萬升,這將(jiang)有力(li)促使公(gong)(gong)(gong)(gong)司(si)(si)通(tong)過(guo)健全(quan)強大的全(quan)球(qiu)供(gong)應鏈(lian)網絡為(wei)客戶提供(gong)符合(he)全(quan)球(qiu)質量標準的生(sheng)物(wu)(wu)(wu)藥(yao)(yao)(yao)。
藥明生(sheng)物是全球開(kai)放式、一(yi)體(ti)化生(sheng)物制(zhi)藥能(neng)力和技術(shu)賦(fu)能(neng)平臺。公司(si)為(wei)全球生(sheng)物制(zhi)藥公司(si)和生(sheng)物技術(shu)公司(si)提(ti)供(gong)端(duan)到端(duan)研(yan)(yan)發(fa)服(fu)務,幫助任(ren)何人、任(ren)何公司(si)發(fa)現、開(kai)發(fa)及生(sheng)產生(sheng)物藥,實現從概念到商業化生(sheng)產的全過程。公司(si)通(tong)過高質量、一(yi)體(ti)化服(fu)務賦(fu)能(neng)全球客戶(hu),提(ti)高研(yan)(yan)發(fa)效率,降(jiang)低(di)研(yan)(yan)發(fa)成本,進一(yi)步加速(su)生(sheng)物藥研(yan)(yan)發(fa)進程。